Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
25.61
-0.20 (-0.79%)
At close: Sep 11, 2026, 4:00 PM EDT
25.10
-0.50 (-1.97%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Buy" and an average price target of $33.93. The average 1-year stock price forecast is 32.51% higher than the current stock price, while the lowest is $25 (-2.36%) and the highest is $45 (+75.75%).
Price Target: $33.93 (+32.51%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 10 | 10 | 9 | 8 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 16 | 16 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $25 | Hold | Maintains | $25 | -2.36% | Sep 1, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $33 → $36 | Buy | Reiterates | $33 → $36 | +40.60% | Aug 10, 2026 |
| Needham | Needham | Buy Maintains $34 | Buy | Maintains | $34 | +32.79% | Aug 4, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $36 → $38 | Buy | Reiterates | $36 → $38 | +48.41% | Jul 28, 2026 |
| UBS | UBS | Buy Reiterates $23 → $31 | Buy | Reiterates | $23 → $31 | +21.07% | Jul 22, 2026 |
Financial Forecast
Revenue This Year
755.34M
from 83.98M
Increased by 799.42%
Revenue Next Year
120.76M
from 755.34M
Decreased by -84.01%
EPS This Year
3.38
from -3.05
EPS Next Year
-1.07
from 3.38
EPS and Forward PE are based on non-GAAP adjusted numbers.